Aclaris Pretax Profit Margin from 2010 to 2024

ACRS Stock  USD 3.63  0.28  7.16%   
Aclaris Therapeutics Pretax Profit Margin yearly trend continues to be comparatively stable with very little volatility. Pretax Profit Margin will likely drop to -2.99 in 2024. From the period from 2010 to 2024, Aclaris Therapeutics Pretax Profit Margin quarterly data regression had mean square error of  65.22 and mean deviation of  15.82. View All Fundamentals
 
Pretax Profit Margin  
First Reported
2010-12-31
Previous Quarter
(2.84)
Current Value
(2.99)
Quarterly Volatility
17.38699249
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 819.9 K, Interest Expense of 3.2 M or Selling General Administrative of 21.3 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0 or PTB Ratio of 0.67. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aclaris Therapeutics Correlation against competitors.
For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Latest Aclaris Therapeutics' Pretax Profit Margin Growth Pattern

Below is the plot of the Pretax Profit Margin of Aclaris Therapeutics over the last few years. It is Aclaris Therapeutics' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Pretax Profit Margin10 Years Trend
Slightly volatile
   Pretax Profit Margin   
       Timeline  

Aclaris Pretax Profit Margin Regression Statistics

Arithmetic Mean(26.97)
Coefficient Of Variation(64.47)
Mean Deviation15.82
Median(41.80)
Standard Deviation17.39
Sample Variance302.31
Range38.9589
R-Value0.89
Mean Square Error65.22
R-Squared0.80
Slope3.48
Total Sum of Squares4,232

Aclaris Pretax Profit Margin History

2024 -2.99
2023 -2.84
2022 -2.92
2021 -13.44
2020 -7.92
2019 -26.86
2018 -13.15

About Aclaris Therapeutics Financial Statements

Aclaris Therapeutics shareholders use historical fundamental indicators, such as Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Pretax Profit Margin(2.84)(2.99)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.